These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
962 related items for PubMed ID: 21376236
1. Activation of mTORC2 by association with the ribosome. Zinzalla V, Stracka D, Oppliger W, Hall MN. Cell; 2011 Mar 04; 144(5):757-68. PubMed ID: 21376236 [Abstract] [Full Text] [Related]
3. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, Dalton JT. Int J Oncol; 2010 Oct 04; 37(4):1023-30. PubMed ID: 20811725 [Abstract] [Full Text] [Related]
11. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN. Nat Cell Biol; 2004 Nov 04; 6(11):1122-8. PubMed ID: 15467718 [Abstract] [Full Text] [Related]
12. PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2. Wahane SD, Hellbach N, Prentzell MT, Weise SC, Vezzali R, Kreutz C, Timmer J, Krieglstein K, Thedieck K, Vogel T. J Neurochem; 2014 Jul 04; 130(2):255-67. PubMed ID: 24645666 [Abstract] [Full Text] [Related]
13. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS. Proc Natl Acad Sci U S A; 2015 Jul 28; 112(30):9406-11. PubMed ID: 26170313 [Abstract] [Full Text] [Related]